Nuvilex Announces Preliminary Data from Preclinical Study of Effects of its Pancreatic Cancer Treatment on Ascites Fluid Formation
SILVER SPRING, MD, November 19, 2014 – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of Nuvilex’s pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by Nuvilex contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.
Preliminary ...
Read More →
19
NOV
Share
Nuvilex Begins Preclinical Studies at Translational Drug Development
SILVER SPRING, Md., Aug. 20, 2014 — Nuvilex, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if Nuvilex’s unique cancer treatment can slow the accumulation of fluid, known as “malignant ascites,” in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President ...
Read More →
20
AUG
Share
Nuvilex Eyes FDA Accelerated Approval Process by Improving Quality of Life in Pancreatic Cancer Patients
Written by ι Stock Market Media Group Staff — May 23, 2014
Nuvilex (OTCQB: NVLX) is calling it a “two pronged attack” on pancreatic cancer, but investors may be calling it an “end-around” or another avenue of sorts, a quicker avenue to FDA approval. This week Nuvilex peeled back another layer of its work with pancreatic cancer, and this time it was to tell the market that the well-respected Translational Drug Development (TD2) will be studying the company’s pancreatic cancer treatment, the combination ...
Read More →
23
MAY
Share
Nuvilex and TD2 Begin Preparations for US-Based Studies on Symptoms Associated With Pancreatic Cancer
SILVER SPRING, Md., May 21, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that, together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer.
TD2 will study the effectiveness of Nuvilex’s ...
Read More →
21
MAY
Share
Nuvilex Adds World Renowned Oncologist and Gastroenterologist to Play Major Role in Late Phase Clinical Trial
SILVER SPRING, Md., May 1, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex’s Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved. Dr. ...
Read More →
1
MAY
Share
Nuvilex, Inc. Applying for Orphan Drug Status to Market Pancreatic Cancer Treatment without Competition
Written by ι Stock Market Media Group — April 22, 2014
When Nuvilex, Inc. (OTCQB: NVLX) named Clinical Network Services (CNS) as the Contract Research Organization (CRO) for its late phase clinical trials in advanced pancreatic cancer, the company also stated it will apply for “Orphan Drug” status. This is a designation that will allow Nuvilex to exclusively market its pancreatic cancer treatment using the Cell-in-a-Box® technology combined with the anticancer drug ifosfamide.
Treatments for pancreatic cancer engender an Orphan Drug designation in most ...
Read More →
22
APR
Share
